OncoMatch/Clinical Trials/NCT06789757
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
Is NCT06789757 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Memantine Hydrochloride and Bevacizumab for hepatocellular carcinoma.
Treatment: Memantine Hydrochloride · Bevacizumab · Atezolizumab — The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: memantine (memantine)
Patients already on memantine for any reason prior to enrollment will be excluded
Lab requirements
Blood counts
Absolute Neutrophil Count ≥ 1,500/μL; Platelets ≥ 100,000/μL; Hemoglobin ≥ 90 g/L (9g/dL)
Kidney function
Creatinine ≤ 2.0 mg/dL; eGFR (using Cockcroft Gault equation) > 40ml/min
Liver function
Childs-Pugh cirrhosis score of A5 or A6; Total Bilirubin ≤ 3 x ULN; AST(SGOT)/ALT(SGPT)/Alkaline Phosphatase ≤ 3 x ULN Or ≤5x ULN if due to liver involvement by tumor
Cardiac function
No significant cardiovascular disease (such as NYHA Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
Patients must have bone marrow and organ function as defined below: Absolute Neutrophil Count ≥ 1,500/μL; Platelets ≥ 100,000/μL; Hemoglobin ≥ 90 g/L (9g/dL); Total Bilirubin ≤ 3 x ULN; AST(SGOT)/ALT(SGPT)/Alkaline Phosphatase ≤ 3 x ULN Or ≤5x ULN if due to liver involvement by tumor; Creatinine ≤ 2.0 mg/dL; eGFR (using Cockcroft Gault equation) > 40ml/min. Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Inova Schar Cancer Institute - Fair Oaks · Fairfax, Virginia
- Inova Health Care Service · Falls Church, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06789757 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages